The phase 3 study findings supported belantamab mafodotin as a potential new standard of care in the second line or later among patients with released/refractory multiple myeloma.
A study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib.
'This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations.'
ELREXFIO™ (elranatamab-bcmm), Now Available from Onco360 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.